Magdalena Biosciences develops prescription medicines derived from a proprietary library of over 2,300 medicinal plants, focusing on mental health conditions such as ADHD and schizophrenia. The company aims to expedite drug development timelines to 12-24 months by leveraging historical medicinal use to enhance the safety and efficacy of its botanical therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Existing treatments for mental health conditions like ADHD and schizophrenia often have limited efficacy or significant side effects. The development of new psychiatric drugs is a lengthy and expensive process, often taking many years to bring a new treatment to market.
Solution
Magdalena Biosciences is developing prescription medicines derived from a library of medicinal plants, focusing on mental health indications. By leveraging the historical use of these plants, Magdalena aims to accelerate drug development timelines and improve the safety and efficacy profiles of its botanical therapies. The company's approach seeks to create novel, safe, and effective psychoactive drugs under FDA Botanical Guidance, with an initial focus on improving executive dysfunction in ADHD and cognitive deficits in schizophrenia.
Target Audience
The primary target audience includes individuals suffering from mental health conditions such as ADHD and schizophrenia, as well as healthcare providers seeking novel and effective treatment options.
Features
- Proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts.
- Focus on developing FDA-approved drugs for daily use.
- Pipeline of IND-enabled drugs for ADHD, schizophrenia, anxiety, and depression.
- Aims for a rapid drug development process, targeting 12-24 months from project commencement to initiation of human proof-of-concept (POC) studies.